Slides
Page 1
Alembic Pharmaceuticals LimitedInvestor Presentation Q2 FY27
Page 2
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 2 Safe Harbour StatementThe materials and information presented herein may include forward looking statements , which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those anticipated.Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product related, forward-looking statements. Product risks and uncertainties include but are not limited to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment, and governmental laws and regulations affecting domestic and foreign operations.Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to the inability to build production capacity to meet demand, unavailability of raw materials, and failure togain market acceptance.
Page 3
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 3 Q2FY27 financial performanceREVENUE₹26.03 bn+36% YoYEBITDA MARGIN+520 bps₹5.78 bn; +78% YoYPAT₹3.35 bn+81% YoYGROSS MARGIN73.7%+70 bps YoYR&D SPEND8%of revenue36%Revenue growthAll businesses registered double digit growthCore margin expansionmargin expansion in base portfolio;funding R&D to build specialty portfolio and the US Branded platformExecutionmomentum across markets- India chronic portfolio gaining momentum - US Branded traction building 14%India 77%US 39%API 12%Ex-US
Page 4
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 4 Robust growth trajectory across businesses 39%28%17%16%Q2 FY27 US FormulationIndia BrandedBusinessEx-US FormulationAPI INR BnY-o-YH1 FY27H1 FY26Q-o-QQ1 FY27Y-o-YQ2 FY27Q2 FY26BusinessFormulations10%13.6712.3813%6.4214%7.256.39India Branded Business64%17.8110.8929%7.7877%10.035.66US 14%8.237.1915%3.8312%4.403.92Ex-US36%7.825.7526%3.4639%4.363.14API31%47.5336.2121%21.5036%26.0319.1Total Revenue
Page 5
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 5 India Branded Business (1/2)19.2620.6322.0023.3924.58 FY22 FY23 FY24 FY25 FY26Revenue TrendCAGR: 6%INR Bn11% y-y growth in Human Health portfolio―growth in Specialty portfolio ~17%; outperforming market―Human Health growth gap vs market narrowingAnimal Health sustained growth momentumAlembic is ranked 20th in the Indian Pharmaceutical Market (IPM); 1.1% market share of the Indian pharma space*Six flagship brands have surpassed INR 1 billion in salesSales operations include 5,800+ Medical Representatives*Source: IQVIA MAT Sep-2617%8%14%13%10%6%9%23%Sales Mix Q2 FY27Anti InfectiveCough & ColdGynecologyCardiologyGastrologyAnti DiabeticOthersAnimal health Growth: 14%3.233.791.781.771.381.69Q2FY26 Q2FY27Revenue Q2 FY27Animal HealthAcuteSpecialtyINR Bn6.397.25
Page 6
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 6 India Branded business (2/2) MS% Q2FY 27*Rank Q2FY 27*BRANDS31.01AZITHRAL88.21ALTHROCIN32.91CRINA-NCR95.41ROXID50.61DELTONE35.01GERIJOINT56.41ELATA6.92CETANIL19.42GESTOFIT SR20.62LACTONIC36.52ESTROPLUS14.52ISOFIT SR19.22TRAVISIGHT14.52UNIGOLIX Top Brands with Rank and Market Share * Above market growth is based on respective molecule group.Alembic ranks 17th by prescription volume, with a total of 137.6 million prescriptions (MAT Sep 2026). MS% Q2FY 27*Rank Q2FY 27*BRANDS9.42FREEGO9.33WIKORYL5.83ISOFIT8.03ULGEL8.83BLADMIR5.03VELDROP10.33OVIGYN DH5.14BROZEET-LS5.14ETRIK12.14CLOFF5.54BILAMBIC-M3.85TELLZY5.35HARMONISource: IQVIA Sep-26 Driving overall Prescription business133.2137.6*Prescriptions (in Mn)MAT Sep-25MAT Sep-260.2440.249*Prescribers (in Mn)Sep-25Sep-26
Page 7
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 7 Animal Health BusinessCAGR: 22%INR BnGrowth: 23%INR BnINR BnAnnual Sales Value0.1 – 0.20.2 – 0.3Above 0.3536No. of BrandsA well-established portfolio of strong brands continues to drive growth-operates in the Livestock, Poultry, and Companion Animal segments.Market leader in Haematinics and Antibiotics with brands such as Sharkoferrol, Moxel , Xceft and Mceft.`33%38%11%11%7%Sales Mix Q2 FY27 Feed Supplement Antibiotic Tonic Supportive TherapyAntiparasitic1.381.69Q2FY26 Q2FY27Revenue Q2 FY272.322.813.554.315.19FY22 FY23 FY24 FY25 FY26Revenue Trend
Page 8
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 8 US Business16.6615.7217.319.5722.06FY22 FY23 FY24 FY25 FY26Revenue TrendINR BnGrowth: 77%INR Bn 1653323222Approved ANDAs Oral SolidsDermaOphthalmicInjectableInhalation10 products launched in H1 FY27 with a total number of 188 products commercialized as on date. Strong and well-diversified pipeline, with a sharper focus on ramping up our presence in complex platforms and specialty segmentsAlembic Therapeutics- Portfolio established; commercial traction is buildingTotal 245** Includes 20 Tentative ApprovalsQ2FY27 : 5 ANDA Filings,1 Approvals.Cumulative : 283 ANDA Filings, 245 approvals and 188 Products Launched so far. CAGR: 7%5.6610.03Q2FY26 Q2FY27Revenue Q2 FY27
Page 9
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 9 Ex-US BusinessCAGR: 18%INR BnGrowth: 12% INR BnGrowth led by Europe, supported by Canada and Emerging market including Chile Leveraging US product portfolio and regulatory approved facilities enabling expansion across key geographiesSubsidiaries incorporated in Germany, Philippines and Thailand for further expansion3.924.40Q2FY26 Q2FY27Revenue Q2 FY277.758.5210.5212.4314.94 FY22 FY23 FY24 FY25 FY26 Revenue Trend
Page 10
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 10 API Business9.3911.6612.4611.3311.87FY22 FY23 FY24 FY25 FY26 Revenue TrendCAGR: 6% INR BnINR BnVolume led growth underpinned by healthy customer demand.1 US DMF filed in Q2 FY27. 153 Cumulative DMF filings with the US FDAContinued focus on cost efficiency to remain competitiveGrowth: 39%3.144.36Q2FY26 Q2FY27Revenue Q2 FY27
Page 11
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 11 R&DContinued investment in building product pipelinesR&D CapabilitiesFormulation & API: Vadodara and Hyderabad Bio Centre :VadodaraRising ANDA filings and approvalsChange in total approvals (Final + Tentative) during the FY8.4 7.2 4.8 5.2 7.1 15.8%12.8%7.6%7.8%9.6%FY22 FY23 FY24 FY25 FY26R&D Spend2320158102124182315FY22 FY23 FY24 FY25 FY26FilingApproval Dosage Form-wise ANDA Approval and Launch – H1 FY27INR BnR&D Spend H1-FY’27INR Bn3.324.071.002.003.004.005.00H1 FY26 H1 FY27*Approval Includes 2 Tentative approvals621252 2101234567OSD OSD-Onco Injectables Derma*Approval (11)Launched (10)
Page 12
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 12 Financials Summary – Profit & Loss statementINR BnParticulars Q-2 FY26 Q-1 FY27 Q-2 FY27 YoY(%) QoQ(%) H1 FY26 H1 FY27 YoY(%)Revenue from Operations 19.10 21.50 26.03 36% 21% 36.21 47.53 31%Other Income 0.07 0.15 0.15 0.13 0.30 124%Total Income 19.17 21.65 26.1937% 21%36.34 47.8332%Material Consumption 5.16 6.20 6.86 33% 11% 9.23 13.06 41%Employee benefits expense 4.38 4.74 5.04 15% 6% 8.60 9.78 14%Finance Costs 0.24 0.28 0.38 58% 39% 0.48 0.66 38%Depreciation & Amortization Expense 0.76 0.98 1.01 33% 3% 1.50 1.99 32%Other Expenses 6.41 7.24 8.51 33% 18% 12.40 15.75 27%Total Expenses16.95 19.43 21.79 29% 12% 32.21 41.23 28%Profit before Share of Profit / (Loss) of Associates 2.22 2.21 4.3998% 98%4.13 6.6160%Share of Profit / (Loss) of Associates & Joint Ventures 0.01 0.00 -0.01 0.01 -0.01Profit Before Tax 2.24 2.22 4.3896% 97%4.14 6.6059%Tax Expense 0.40 0.49 1.04 0.76 1.54Profit for the Period 1.84 1.72 3.3482% 94%3.37 5.0650%Non-controlling interests 0.01 0.01 0.01 0.02 0.02Profit for the Period attributable to shareholders 1.85 1.73 3.3581% 94%3.39 5.0850%Gross Margin73% 71% 74% 74% 73%EBIDTA Margin17% 16% 22% 17% 19%PBT Margin12% 10% 17% 11% 14%PAT Margin10% 8% 13% 9% 11%R&D Expenses as % Revenue10% 9% 8% 9% 9%
Page 13
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 13 Financials Summary – Balance sheetAs at 31st March, 2026As at 30th September, 2026Non-current assetsProperty, plant and equipment28.44 29.14Capital work-in-progress6.34 5.43Other Intangible assets 2.37 3.28Intangible assets under development0.50 0.51Financial Assets 1.41 1.53Deferred tax assets2.70 2.61Other non-current assets0.15 0.2941.90 42.78Current assetsInventories25.11 26.54Trade receivables14.66 18.96Cash and cash equivalents1.96 2.54Bank balances other than cash and cash equivalents0.06 0.08Other financial assets0.14 0.14Current Tax Assets0.11 0.21Other current assets3.38 3.7645.43 52.23Assets classified as held for sale0.30 0.30TOTAL - ASSETS87.63 95.31EquityEquity Share capital0.39 0.39Other Equity56.35 59.05Equity attributable to owners of the Company56.75 59.44Non-controlling interests-0.06 -0.08Total Equity56.69 59.37Non-current liabilitiesBorrowings1.22 0.91Lease liabilities0.45 0.32Provisions1.53 1.66Other Non current Liability1.80 2.085.00 4.96Current liabilitiesBorrowings12.39 13.99Lease liabilities0.24 0.25Trade payables8.35 11.59Other financial liabilities2.79 1.70Other current liabilities0.71 1.02Provisions1.11 1.19Current Tax Liabilities0.35 1.2425.94 30.99TOTAL 87.63 95.31 INR Bn
Page 14
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. Company Overview
Page 15
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 15 Company at a GlanceANDA Filings283 (Sep 30,2026)R&D Centers2Manufacturing Facilities9Brands209Field Force5,800+Net Zero Target2050Generics Formulation in the USA188Team Size17,200+MissionImprove Healthcare with innovation, commitment and TrustPrescribers in India~2,49,000
Page 16
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 16 Value Proposition Developing a specialty drug pipeline for India Supplying APIs to 60+ countries globally Exploring opportunities in InjectablesEstablished presence in Chile & UAE20Ranks 20th in the Indian formulations marketExpanding product portfolio in the USA Strengthening presence in Canada, South Africa, LATAM & Middle East Consistent dividend payout track record
Page 17
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 17 The Journey1907Established by the Amin Family2006FDA-approved API facility2007Acquired Dabur’s Indian Cardiology, GI & Gynecology brands2008FDA-approved Formulation facility2009Multiple divisions to address chronic therapies launched2013Launched first NDA with a partner. Commenced filing in the EU, Australia & Brazil2010Pharmaceutical business demerged from the Alembic Group2015Launched Aripiprazole. Established US front-end transition to direct marketing2012Formed a JV, Rhizen , for NCE Research2016Formed a JV, Aleor , for dermatology portfolio2019Azithral crossed Rs . 250 crore mark as per ORG IMS, MAT Dec 20192022Azithral ranked 16thhighest selling brand. AleorDermaceuticalsmerged with Alembic Pharma2023Started commercialization of products from Injectables and Oncology facilities2025Indore facility Commissioned & Acquired Utility Therapeutics Limited2026• Expanded into the US branded footprint through Alembic Therapeutics.•Formed Canadian JV, for Product Commercialization
Page 18
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 18 Product brand logo Robust InfrastructureF2 - Panelav F3 - Karkhadi Last USFDA AuditDosage FormLocationInternational GenericsJuly’24General Oral SolidsF1 - PanelavMar’24Oncology Oral SolidsF2 - PanelavOct’24Oncology InjectablesFeb’26General Injectables & OphthalmicF3 - KarkhadiNov’24General Oral SolidsF4 - JarodMar’23Various derma formsF5 - KarkhadiAPIMay’25API I & II – PanelavMar’25API III - Karkhadi F4 - Jarod F5 - Karkhadi. Last WHO AuditDosage FormLocation Mar’26*Oral Solids & LiquidIndia Formulation-Indore* Certification received in Apr’26.
Page 19
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 19 ESG: Goals on Track & Key AchievementsCOMMITMENTPROGRESSKEY HIGHLIGHTS Net Zero by 205063% Emission Reduction by 203490% Emission Reduction by 205010.7%Absolute GHG emission reduction (Scope 1, 2 & 3)10.7% absolute reduction in Scope -1,2&3 (GHG Emission) from base year FY 2022-23Achieved Share of renewable power in total power mix to 69% Water Neutrality by 2027100%Water neutrality achieved (Water Positive)Developed 112 Recharge Well + Check Dam which is equivalent to >100% of total water consumption. (Water Positive)71% Recycling Rate as a result of robust treatment of wastewater 50,000 Tree Plantation by 202780%Of plantation target achieved (40,000+ of 50,000)40,000+ trees are planted out of which 22,450 are through Miyawaki Afforestation techniqueFourth phase of 10,000 trees plantation is initiatedOTHER ACHIEVEMENTSZeroFatality in last five years3,00,000+Beneficiaries through CSR64%ESG Score in Crisil ESG Ratings100%Recycling of plastic waste
Page 20
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 20 Yearly Financials #Note : FY23 numbers are without considering one-time impact of Aleor write off for better comparison14% #15%16%16%FY23 FY24 FY25 FY26EBIDTA margin %56.5362.2966.7273.45FY23 FY24 FY25 FY26Revenue4.123.455.754.32FY23 FY24 FY25 FY26Capex7.79 #9.6110.5311.77FY23 FY24 FY25 FY26EBIDTA14% *#15%*16% *15%*FY23 FY24 FY25 FY26ROCE %4.97 #6.165.846.75FY23 FY24 FY25 FY26Net ProfitINR Bn * Excluding Assets not deployed & Exceptional Items.
Page 21
Investor Presentation Q2 FY27Alembic Pharmaceuticals Ltd. 21 Awards and Ratings “Best Overall Sustainable Performance” award at TheGujarat State Leadership Awards 2026 (10thEdition)byWorld Leadership Congress & Awards. “Sustainability Champion of the Year 2025”award at25thEnvironment and Sustainability Awards 2026organized byrenownedGreentech Foundation. 6413thposition out of 48 Pharma Companies
Page 22
2ndFloor, Prime Corporate Park Sahar Road, Andheri East Mumbai 400 099www.alembicpharmaceuticals.com Thank YouFor further queries, please contact:Ms. Isha Lambaisha.lamba@alembic.co.in022-6695 1652Investor Relations AdvisorsAdfactors PR Pvt. Ltd.Snighter Albuquerquesnighter.a@adfactorspr.comDarshan Mankaddarshan.mankad@adfactorspr.com